What is the current market size and future outlook for the cholestatic pruritus market?
The cholestatic pruritus market size has grown strongly in recent years. It will grow from $19.20 billion in 2024 to $20.28 billion in 2025 at a compound annual growth rate (CAGR) of 5.6%. The growth in the historic period can be attributed to the rising prevalence of skin disorders, growing investments in research and development, demand for effective treatments, rising awareness of the disease, and favorable regulatory environments.
The cholestatic pruritus market size is expected to see strong growth in the next few years. It will grow to $24.97 billion in 2029 at a compound annual growth rate (CAGR) of 5.3%. The growth in the forecast period can be attributed to the increasing elderly population, increasing prevalence of atopic dermatitis and urticaria, increase in the geriatric population, increase in chronic kidney diseases, and growing prevalence of conditions associated with pruritus. Major trends in the forecast period include the introduction of new treatment options, partnerships with major businesses for cholestasis pruritus research, innovation in treatment modalities, expansion of healthcare facilities, and technological innovation.
Get Your Free Sample of The Global Cholestatic Pruritus Market Report:
https://www.thebusinessresearchcompany.com/sample.aspx?id=21140&type=smp
How has the cholestatic pruritus market evolved, and what factors have shaped its growth?
The increasing prevalence of liver diseases is expected to propel the growth of the cholestatic pruritus market going forward. Liver diseases are a broad range of conditions that affect liver function, including infections, autoimmune disorders, genetic diseases, and damage from toxins, leading to inflammation, scarring, or liver failure. The growing prevalence of liver diseases is fueled by increasing obesity, diabetes, alcohol use, viral hepatitis infections, and exposure to toxins and environmental factors. Cholestatic pruritus helps in the identification and management of liver diseases by serving as a key symptom that indicates impaired bile flow, often prompting further investigation and treatment of underlying hepatic conditions. For instance, in July 2023, according to the Office for Health Improvement and Disparities, a UK-based government body focused on addressing health inequalities, hospital admissions for liver disease in England increased by 22% in the year ending 2022, rising from 67,458 to 82,290. Therefore, the increasing prevalence of liver diseases will drive the growth of the cholestatic pruritus market.
What are the major segments of the cholestatic pruritus market?
The cholestatic pruritus market covered in this report is segmented –
1) By Disease Type: Primary Biliary Cholangitis (PBC), Primary Sclerosing Cholangitis (PSC), Intrahepatic Cholestasis of Pregnancy (ICP), Other Disease Types
2) By Treatment Type: Medications, Phototherapy, Other Treatment Types
3) By Route Of Administration: Oral, Topical, Injectable
4) By End-User: Hospitals, Clinics, Ambulatory Care Centers, Homecare
Subsegments:
1) By Primary Biliary Cholangitis (PBC): Early-Stage PBC, Advanced PBC, PBC With Cirrhosis, PBC With Liver Failure
2) By Primary Sclerosing Cholangitis (PSC): Classic PSC, PSC With Ulcerative Colitis, PSC With Bile Duct Strictures
3) By Intrahepatic Cholestasis of Pregnancy (ICP): Mild ICP, Severe ICP, ICP With Preterm Birth Risk
4) By Other Disease Types: Alcoholic Cholestasis, Drug-Induced Cholestasis, Viral Hepatitis-Induced Cholestasis, Genetic Cholestasis Disorders
Order your report now for swift delivery
https://www.thebusinessresearchcompany.com/report/cholestatic-pruritus-global-market-report
Which companies dominate the cholestatic pruritus market?
Major companies operating in the cholestatic pruritus market are GlaxoSmithKline plc, Takeda Pharmaceutical Company Limited, Merck KGaA, Regeneron Pharmaceuticals Inc., Bausch Health Companies Inc., Incyte Corporation, Ipsen Pharma, Vanda Pharmaceuticals Inc., Medison Pharma Ltd., Mirum Pharmaceuticals Inc., Albireo Pharma Inc., Dipharma Francis S.r.l., Cara Therapeutics Inc., CANbridge Pharmaceuticals Inc., Escient Pharmaceuticals Inc., Tharimmune Inc., Vifor Fresenius Medical Care Renal Pharma, CymaBay Therapeutics Inc., ICE Pharma Inc., Aquatic Remedies Private Limited.
How will evolving trends contribute to the growth of the cholestatic pruritus market?
Major companies operating in the cholestatic pruritus market are focusing on developing innovative solutions, such as oral solutions to manage symptoms more effectively, improve patient compliance, and provide targeted relief by addressing the underlying causes of bile salt accumulation and inflammation. An oral solution for the treatment of cholestatic pruritus is a liquid formulation of medication designed to reduce bile acid accumulation and alleviate severe itching in patients with cholestasis. For instance, in March 2024, Mirum Pharmaceuticals Inc., a US-based biopharmaceutical company, received approval from the U.S. Food and Drug Administration (FDA) for LIVMARLI (maralixibat) oral solution for treating cholestatic pruritus in patients aged five and older with progressive familial intrahepatic cholestasis (PFIC). This once-daily, orally administered ileal bile acid transporter inhibitor holds a breakthrough therapy designation for PFIC type 2. LIVMARLI is poised to make a significant impact on patients with cholestatic pruritus linked to PFIC, offering a much-needed treatment option for those with the rarest subtypes.
What are the key regional dynamics of the cholestatic pruritus market, and which region leads in market share?
North America was the largest region in the cholestatic pruritus market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the cholestatic pruritus market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
What Does The Cholestatic Pruritus Market Report 2025 Offer?
The cholestatic pruritus market research report from The Business Research Company offers global market size, growth rate, regional shares, competitor analysis, detailed segments, trends, and opportunities.
Cholestatic pruritus refers to severe itching caused by the buildup of bile acids in the skin, typically resulting from liver diseases that impair bile flow. This condition can significantly affect a patient’s quality of life and often requires targeted treatment to manage the discomfort and address the underlying liver dysfunction.
Purchase the exclusive report now to unlock valuable market insights:
https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=21140
With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead.
Our flagship product, the Global Market Model, is a premier market intelligence platform delivering comprehensive and updated forecasts to support informed decision-making.
Contact Us:
The Business Research Company
Europe: +44 207 1930 708
Asia: +91 88972 63534
Americas: +1 315 623 0293
Email: info@tbrc.info
Follow Us On:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
Twitter: https://twitter.com/tbrc_info
Facebook: https://www.facebook.com/TheBusinessResearchCompany
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Blog: https://blog.tbrc.info/
Healthcare Blog: https://healthcareresearchreports.com/
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model
